Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 5, 2022 07:15PM
Fluidigm (FLDM) Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc. Apr 4, 2022 05:32PM
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc. Apr 4, 2022 05:30PM
Fluidigm (FLDM) Announces Stockholders Approve $250 Million Strategic Capital Infusion Apr 1, 2022 04:06PM
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion Apr 1, 2022 04:05PM
View Older Stories

Mar 29, 2022 09:30AM Fluidigm (FLDM) Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Mar 29, 2022 09:29AM Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Mar 28, 2022 08:33AM Fluidigm (FLDM) Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
Mar 28, 2022 08:30AM Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
Mar 25, 2022 04:00PM Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
Mar 21, 2022 08:00AM Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Mar 17, 2022 05:58PM Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
Feb 18, 2022 05:37AM Fluidigm (FLDM) Reports Q4 Revenue of $38.3M, Net Loss of $0.8M
Feb 17, 2022 05:43PM Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results 
Feb 17, 2022 08:30AM Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies
Feb 14, 2022 06:11AM Fluidigm (FLDM) Files Prelim Proxy Statement for Proposed $250M Investment from Casdin Capital and Viking Global Investors
Feb 14, 2022 06:10AM Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
Jan 24, 2022 08:34AM Fluidigm (FLDM) Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.
Jan 24, 2022 08:30AM Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.
Jan 11, 2022 08:00AM Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021
Dec 7, 2021 08:32AM Fluidigm's (FLDM) Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant
Dec 7, 2021 08:30AM Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant of COVID-19
Nov 16, 2021 08:30AM Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 11, 2021 08:30AM Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost
Nov 8, 2021 04:02PM Fluidigm Announces Third Quarter 2021 Financial Results
Nov 8, 2021 08:30AM Imaging Mass Cytometry Utilized to Seek Molecular Links between African Ancestry and Aggressive Forms of Breast and Prostate Cancer
Oct 20, 2021 08:30AM Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
Oct 18, 2021 08:30AM Fluidigm 2021 IMC Summit Focuses on ‘Uncovering Spatial Biology’
Oct 12, 2021 08:33AM Fluidigm (FLDM) Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software
Oct 12, 2021 08:30AM Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software
Sep 28, 2021 08:32AM Fluidigm (FLDM) Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT
Sep 28, 2021 08:30AM Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT
Sep 2, 2021 08:30AM Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
Aug 31, 2021 08:30AM CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2
Aug 9, 2021 11:14AM Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
Aug 5, 2021 04:05PM Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
Aug 5, 2021 08:35AM Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry
Aug 5, 2021 08:30AM Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine
Jul 8, 2021 04:01PM Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
May 25, 2021 02:00PM Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership
May 24, 2021 08:30AM Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis
May 14, 2021 08:30AM Fluidigm to Present at Upcoming Investor Conferences
May 10, 2021 01:30PM Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
May 6, 2021 04:05PM Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
May 6, 2021 08:33AM Fluidigm (FLDM) Announces Data Published in Nature Communications Demonstrate Power of CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery
May 6, 2021 08:30AM Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approac
Apr 8, 2021 08:30AM Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results
Mar 1, 2021 08:33AM Fluidigm (FLDM) Announces FDA Grants EUA for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay
Mar 1, 2021 08:30AM FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay
Feb 10, 2021 04:05PM Fluidigm (FLDM) Enters Agreement with Zhejiang PuLuoTing Health Technology Co. Ltd in China
Feb 10, 2021 04:05PM Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 10, 2021 04:02PM Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China
Feb 10, 2021 04:02PM George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
Feb 9, 2021 08:30AM NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients
Feb 4, 2021 04:02PM Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
View Older Stories